CD9 Antibody (P1/33/2): sc-20048

CD9 Antibody (P1/33/2) is a mouse monoclonal IgG1 kappa light chain antibody raised against a common acute lymphoblastic leukemia antigen, reactive with mouse, rat, and human species, and validated for applications including western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). CD9, also known as Tetraspanin-29, is a type IV transmembrane glycoprotein with four transmembrane domains and is predominantly located on the plasma membrane of various cell types, including early B cells, eosinophils, basophils, activated T cells, and platelets. CD9 (P1/33/2) antibody′s cell surface localization is critical for mediating cell-cell adhesion and facilitating interactions between adjacent cells, which is essential for immune responses, tissue repair, and cellular signaling. CD9 monoclonal antibody (P1/33/2) is also involved in signal transduction pathways through interactions with low molecular weight GTP-binding proteins, impacting intracellular processes such as migration, proliferation, and adhesion. CD9 is a major component of the platelet surface, playing a key role in platelet aggregation and hemostasis. Additionally, CD9 is expressed in various hematological malignancies, including most non-T acute lymphoblastic leukemia cells and some acute myeloid and chronic lymphoid leukemias, making CD9 (P1/33/2) monoclonal antibody an important marker for diagnostic and research purposes. Anti-CD9 antibody (P1/33/2) provides a versatile tool for studying the function, cellular localization, and pathological roles of this critical transmembrane protein and is available in non-conjugated form, suitable for a wide range of experimental applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD9 Antibody (P1/33/2) References:

1. Novel CD9-targeted therapies in gastric cancer.  |  Murayama, Y., et al. 2015. World J Gastroenterol. 21: 3206-13. PMID: 25805926
2. An emerging role of CD9 in stemness and chemoresistance.  |  Ullah, M., et al. 2019. Oncotarget. 10: 4000-4001. PMID: 31258843
3. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9.  |  Mathieu, M., et al. 2021. Nat Commun. 12: 4389. PMID: 34282141
4. Prognostic value and multifaceted roles of tetraspanin CD9 in cancer.  |  Ondruššek, R., et al. 2023. Front Oncol. 13: 1140738. PMID: 37007105
5. Lack of involvement of CD63 and CD9 tetraspanins in the extracellular vesicle content delivery process.  |  Tognoli, ML., et al. 2023. Commun Biol. 6: 532. PMID: 37198427
6. Differential proteomics argues against a general role for CD9, CD81 or CD63 in the sorting of proteins into extracellular vesicles.  |  Fan, Y., et al. 2023. J Extracell Vesicles. 12: e12352. PMID: 37525398
7. CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway.  |  Li, Y., et al. 2023. iScience. 26: 108070. PMID: 37860696
8. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.  |  Leung, KT., et al. 2024. Leukemia. 38: 250-257. PMID: 38001171
9. CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects.  |  Zheng, Y., et al. 2024. Adv Sci (Weinh). 11: e2400819. PMID: 38837628
10. Distinctive CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis.  |  Han, S., et al. 2024. Nat Commun. 15: 8628. PMID: 39366998

The preferred CD9 antibody is CD9 Antibody (C-4): sc-13118.